News and Trends 28 Jan 2019 New UK Policy Benefits Biotechs Waging War on Superbugs Among other measures, the new policy changes the way companies are reimbursed for antimicrobial drugs, which is expected to increase investment in biotech and the interest of big pharma in tackling antimicrobial resistance. Antimicrobial resistance is a huge problem. More and more pathogens are becoming resistant to antibiotics, as seen in the rising number of […] January 28, 2019 - 4 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Startup Scout 18 Jan 2019 This Biotech Turns Rejected Organs Into Drug Testing Models Engitix, a spinout from University College London, makes accurate disease models from human tissue that include the extracellular matrix from outside of the cells, an often overlooked but essential factor in the way cells behave inside our bodies. Mission: To make disease models in the lab that include the extracellular matrix, making them more […] January 18, 2019 - 4 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Startup Scout 11 Jan 2019 This Company Automates Cancer Research from Bench to Bar Charts In the academic city of Oxford, UK, the company Arctoris is working to make life easier for cancer lab researchers, letting them ‘order’ experiments online using its robotic facilities and data analysis tools. Mission: To cut down researchers’ workloads by automating cellular, molecular, and data analysis techniques in cancer research. As any molecular biologist will […] January 11, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 8 Jan 2019 Topical Gene Therapy Shows Early Promise for Inherited Skin Disease A gene therapy applied to the skin, developed by UK company Amryt Pharma, showed positive preclinical results for the treatment of a rare genetic skin disease. The disease, called recessive dystrophic epidermolysis bullosa (RDEB), is one of a group of diseases in which sufferers have mutations in proteins vital to the integrity of the […] January 8, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 7 Jan 2019 AI Drug Discovery Company Raises €23M and Signs with Roche Oxford-based Exscientia has closed a €23M ($26M) Series B round and announced a partnership with Roche worth up to €60M. Exscientia has developed an artificial intelligence platform to boost drug discovery in pharma and biotech. “We can reduce at least 4- to 5-fold the time and cost of drug discovery as compared to the industry […] January 7, 2019 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
More News! 20 Dec 2018 Cambridge Company Raises €20M for Potential First in Lung Disease Morphogen-IX, based in Cambridge, has raised €20.4M (£18.4M) to fund a new type of treatments for pulmonary arterial hypertension. The Series B financing will go towards the preclinical development of the company’s lead candidate, which has the potential to become the first to treat the condition rather than just addressing the symptoms. People with pulmonary […] December 20, 2018 - 1 minutemin - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 17 Dec 2018 Series B Boosts British Biotech’s Cell Therapy Automation With €22.6M The UK company Synthace has raised €22.6M to develop its software platform to automate and improve the manufacturing process in gene and cell therapy. The round, led by Hong Kong-based investor Horizons Ventures, will help to fund the development of Synthace’s software designed to automate key protocols in the lab. Furthermore, the funding will help […] December 17, 2018 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 11 Dec 2018 UK Biotech Settles Lawsuit on the First RNAi Drug Silence Therapeutics and Alnylam have reached a settlement that puts an end to a legal dispute between them resulting in Silence receiving some royalties on Onpattro, the first RNA interference drug. The lawsuit started last year, when Silence went to the UK courts claiming that Alnylam was infringing on its intellectual property. As part of […] December 11, 2018 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
More News! 10 Dec 2018 British Company Raises €37M to Personalize Therapies with Machine Learning Genomics, a company based in Oxford, has increased the amount raised in a Series B round that will fund further development of its genomics technology for personalized medicine. The company adds a further €9M (£8M) to the round with the participation of Foresite Capital and F-Prime Capital, two renowned US life sciences investors. The previous […] December 10, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 7 Dec 2018 Orchard’s Gene Therapy for Rare Immune Disease Works for Over a Year A single dose of a gene therapy developed by Orchard Therapeutics can restore immune function for at least a year in patients with X-linked chronic granulomatous disease (X-CGD). The gene therapy was trialed in patients between the ages of 2 and 27 with the rare disease, which is caused by a rare genetic mutation that […] December 7, 2018 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 6 Dec 2018 Update: Liver Gene Therapy 8 Times Stronger Than Usual Update (06/12/2018): uniQure has incorporated Synpromics’ strong liver promoter into a preclinical gene therapy candidate for treating hemophilia A. Published on 08/10/2018 Synpromics and uniQure have unveiled new technology for precise genetic control that could make gene therapy safer and more precise. The team has developed a gene therapy system that is highly selective for […] December 6, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 30 Nov 2018 Update: UK Biotech Scores £5M Series A to Boost Next-Generation Cancer Antibodies Update (30/11/2018): IGEM Therapeutics has increased the total raised in Series A to £5M (€5.6M) with the participation of two new investors, Alsa Holdings and UCL Technology Fund. The funding will go towards the development of a new generation of antibody drugs for cancer. Published on 20/06/2017 IGEM Therapeutics has raised £2M (€2.3M) in Series A […] November 30, 2018 - 2 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email